CN113456684A - Application of artemisia scoparia in preparation of medicine for treating pulmonary fibrosis - Google Patents
Application of artemisia scoparia in preparation of medicine for treating pulmonary fibrosis Download PDFInfo
- Publication number
- CN113456684A CN113456684A CN202110916462.8A CN202110916462A CN113456684A CN 113456684 A CN113456684 A CN 113456684A CN 202110916462 A CN202110916462 A CN 202110916462A CN 113456684 A CN113456684 A CN 113456684A
- Authority
- CN
- China
- Prior art keywords
- artemisia scoparia
- artemisia
- pulmonary fibrosis
- scoparia
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000003069 Artemisia scoparia Nutrition 0.000 title claims abstract description 120
- 241001249148 Artemisia scoparia Species 0.000 title claims abstract description 120
- 208000005069 pulmonary fibrosis Diseases 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title description 16
- 239000000284 extract Substances 0.000 claims description 35
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 35
- 210000002966 serum Anatomy 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 20
- 229940118019 malondialdehyde Drugs 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 3
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 241000700159 Rattus Species 0.000 description 22
- 235000019441 ethanol Nutrition 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 229960003180 glutathione Drugs 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- -1 superoxide anion free radical Chemical class 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 108010006654 Bleomycin Proteins 0.000 description 6
- 229960001561 bleomycin Drugs 0.000 description 6
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000003456 pulmonary alveoli Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 235000003826 Artemisia Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 244000030166 artemisia Species 0.000 description 2
- 235000009052 artemisia Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000004879 pulmonary tissue Anatomy 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LHTXICJJDIGXGN-HNGAPHHWSA-N (8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione hydrochloride Chemical compound Cl.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 LHTXICJJDIGXGN-HNGAPHHWSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000013479 Amaranthus retroflexus Nutrition 0.000 description 1
- 244000055702 Amaranthus viridis Species 0.000 description 1
- 235000004135 Amaranthus viridis Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000202903 Bergenia purpurascens Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241001061906 Caragana Species 0.000 description 1
- 235000009344 Chenopodium album Nutrition 0.000 description 1
- 235000005484 Chenopodium berlandieri Nutrition 0.000 description 1
- 235000009332 Chenopodium rubrum Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XOSXWYQMOYSSKB-LDKJGXKFSA-L water blue Chemical compound CC1=CC(/C(\C(C=C2)=CC=C2NC(C=C2)=CC=C2S([O-])(=O)=O)=C(\C=C2)/C=C/C\2=N\C(C=C2)=CC=C2S([O-])(=O)=O)=CC(S(O)(=O)=O)=C1N.[Na+].[Na+] XOSXWYQMOYSSKB-LDKJGXKFSA-L 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an application of artemisia scoparia in preparing a medicine for treating pulmonary fibrosis.
Description
Technical Field
The invention relates to application of artemisia scoparia to preparation of a medicine for treating pulmonary fibrosis.
Background
Pulmonary fibrosis is a chronic inflammatory interstitial lung disease with unknown reasons, such as interstitial pneumonia and lung diseases caused by connective tissues, which can cause pulmonary fibrosis. In recent years, the incidence rate of pulmonary fibrosis gradually rises, the mortality rate is high, the harm to human health is serious, and the worldwide attention is attracted. Patients with pulmonary fibrosis are clinically mainly manifested by progressive dyspnea, finally develop hypoxemia and respiratory failure and die, and the average survival time after diagnosis is 3 years. The pulmonary fibrosis is complicated in pathogenesis, unclear in mechanism and lack of effective treatment medicines. At present, immunosuppressive drugs and glucocorticoid drugs are mainly used for clinically treating pulmonary fibrosis, but the curative effect is not obvious and the toxic and side effects are caused.
Binchao refers to Artemisia scoparia L. Artemisia scoparia Waldst et Kit (academic name) is perennial herb or herb of nearly one or two years of Artemisia in Compositae; the plants have strong fragrance. Artemisia scoparia is bitter, pungent and slightly cold in taste. Clear heat and remove dampness, promote bile flow and relieve jaundice. It is commonly used for icterohepatitis, oliguria, yellowish complexion, cholecystitis, and early stage of damp-warm disease.
CN101669979B discloses artemisia scoparia extract and a production method and application thereof. The method for producing artemisia scoparia extract comprises the following steps: firstly, extracting the overground part or the whole grass of artemisia scoparia with water or ethanol in a coarse way; secondly, filtering and concentrating the extracting solution, adding absolute ethyl alcohol, standing for precipitation, and filtering the precipitate to obtain an ethanol solution; thirdly, concentrating the obtained ethanol solution, adjusting the pH value, and adsorbing by using a macroporous resin and/or polyamide resin chromatographic column; step four, gradient elution is carried out by 10 to 90 percent of ethanol, and ethanol eluates are collected and merged; and fifthly, concentrating the obtained eluent, recovering ethanol, and drying under reduced pressure to obtain the artemisia scoparia extract. The patent document reports that artemisia scoparia extract has the effects of resisting influenza virus, hepatitis b virus and AIDS virus.
CN105832793A discloses the application of artemisia scoparia extract in preparing medicine for treating pneumonia caused by streptococcus pneumoniae or/and beta hemolytic streptococcus.
CN103638098A discloses a Tibetan medicine composition for treating respiratory tract, the effective components of which are prepared from the following raw materials in parts by weight: 4-7 parts of bergenia purpurascens, 1-3 parts of crab caragana, 1-3 parts of artemisia pigweed and 1-3 parts of liquorice.
In conclusion, no report about the application of artemisia scoparia in preparing the medicine for treating pulmonary fibrosis is found.
Disclosure of Invention
The invention aims to provide application of artemisia scoparia to preparation of a medicine for treating pulmonary fibrosis.
The purpose of the invention is realized by the following technical scheme.
The invention provides an application of artemisia scoparia in preparing a medicine for treating pulmonary fibrosis.
According to the use of the invention, preferably, the artemisia scoparia is artemisia scoparia medicinal material powder or an artemisia scoparia extract.
According to the use of the invention, preferably, the artemisia scoparia is an artemisia scoparia extract.
According to the use of the invention, preferably, the medicament forms a medicament preparation for treating pulmonary fibrosis, and the medicament preparation contains artemisia scoparia and pharmaceutically acceptable auxiliary materials.
According to the application, preferably, the artemisia scoparia is the only active ingredient in the medicine for treating pulmonary fibrosis.
According to the use of the present invention, preferably, the medicament forms a pharmaceutical preparation for increasing the content of superoxide dismutase and the content of reduced glutathione in serum.
According to the use according to the invention, preferably, the medicament forms a pharmaceutical preparation for reducing the content of malondialdehyde in serum.
According to the use of the invention, preferably, the artemisia scoparia extract is prepared by the following steps:
soaking the sieved artemisia scoparia medicinal material powder in water, heating and refluxing for extraction for 1-4 times, carrying out solid-liquid separation, combining water extract, and concentrating to obtain an artemisia scoparia extract; wherein the amount of water used in each time is 8-15 times of the weight of the artemisia scoparia medicinal material powder, and the soaking time is 2-6 hours; the time for each extraction is 2-6 h.
According to the application, preferably, the unit dose of the pharmaceutical preparation contains 0.95-3.95 g of artemisia scoparia extract.
According to the application, 1.15-3.90 g of artemisia scoparia extract is preferably contained in the pharmaceutical preparation with unit dose.
The artemisia scoparia can intervene in a rat pulmonary fibrosis model established by tracheal instillation of bleomycin. Herba Artemisiae Scopariae can reduce collagen fiber in stroma. Furthermore, the artemisia scoparia can obviously improve the contents of SOD and GSH in serum and obviously reduce the content of MDA in the serum.
Drawings
Fig. 1 shows the effect of artemisia scoparia on HE staining of rats with pulmonary fibrosis.
FIG. 2 shows the effect of different amounts of artemisia scoparia on Masson staining of rats with pulmonary fibrosis.
FIG. 3 shows the results of measuring the SOD content in rat serum in each group.
FIG. 4 shows the results of measuring the amount of GSH in the serum of rats in each group.
FIG. 5 shows the results of measuring the amount of MDA in rat serum in each group.
In FIGS. 1 to 5, CON represents a blank control group, MOD represents a model control group, LPL represents a artemisia scoparia low dose group (100mg/kg), LPM represents a artemisia scoparia medium dose group (200mg/kg), LPH represents a artemisia scoparia high dose group (400mg/kg), and PRE represents a positive control group.
Detailed Description
The present invention will be further described with reference to the following specific examples, but the scope of the present invention is not limited thereto.
The invention provides an application of artemisia scoparia in preparing a medicine for treating pulmonary fibrosis.
In the present invention, artemisia scoparia can be an artemisia scoparia medicinal material, such as artemisia scoparia medicinal material powder. The artemisia scoparia can be an artemisia scoparia extract, such as an artemisia scoparia extract disclosed in CN 101669979B.
According to one embodiment of the invention, artemisia scoparia is an artemisia scoparia extract.
According to one embodiment of the invention, the artemisia scoparia extract is prepared by the following steps: heating and refluxing the sieved artemisia scoparia medicinal material powder with water for 1-4 times, carrying out solid-liquid separation, combining water extracting solutions and concentrating to obtain an artemisia scoparia extract; wherein the amount of water used in each time is 8-15 times of the weight of the artemisia scoparia medicinal material powder, and the extraction time is 2-6 hours each time.
In the invention, the heating reflux extraction can be performed for 1 to 4 times, preferably for 2 to 4 times, and more preferably for 2 to 3 times. The amount of water used in each extraction can be 8-15 times, preferably 8-12 times, and more preferably 9-11 times of the mass of the sieved artemisia scoparia medicinal material powder. The time for each extraction can be 2-6 h, preferably 3-6 h, and more preferably 2-5 h. Thus, the artemisia scoparia extract with better required performance can be extracted to the maximum extent, and the cost can be saved.
In the invention, the artemisia scoparia medicinal material can be crushed and then screened by a No. 2 screen. Before each extraction, the screened artemisia scoparia medicinal material powder is soaked in water for 2-6 hours, preferably 3-6 hours, and more preferably 3-5 hours. This is advantageous for a greater extraction of the desired artemisia scoparia extract. According to a specific embodiment of the invention, the artemisia scoparia medicinal material is crushed and sieved by a No. 2 sieve, the sieved artemisia scoparia medicinal material powder is soaked in water, and is heated, refluxed and extracted for 1 to 4 times, and solid and liquid are separated; mixing the water extractive solutions, and concentrating to obtain herba Artemisiae Scopariae extract; wherein the amount of water used in each time is 8-15 times of the mass of the sieved artemisia scoparia medicinal material powder, the soaking time is 2-6 hours, and the extraction time is 2-6 hours. Refrigerating the obtained artemisia scoparia extract at 4-6 ℃, and diluting and dissolving the artemisia scoparia extract in water when the artemisia scoparia extract is used to obtain the dosage.
In the present invention, the obtained artemisia scoparia extract is substantially free of water.
The medicine can form a medicinal preparation for treating pulmonary fibrosis, and the medicinal preparation contains artemisia scoparia and pharmaceutically acceptable auxiliary materials.
In the invention, the medicine for treating pulmonary fibrosis can be a raw material medicine or a preparation. The formulation of the preparation may be any pharmaceutical formulation, and is not particularly limited. Preferably, the dosage form is an oral dosage form. The oral dosage form may be a sustained or controlled release dosage form, such as sustained release capsules, sustained release tablets, and the like. For example, the dosage form is a tablet, a pill, a capsule, a granule, a suspension, an oral liquid, and the like.
In the invention, the drug for treating pulmonary fibrosis can contain pharmaceutically acceptable auxiliary materials. The kind of the pharmaceutically acceptable auxiliary material is not limited. When the medicament is an oral preparation, the adjuvant may be selected from one or more of diluents, binders, disintegrants and lubricants. The diluent includes, but is not limited to, one or more of mannitol, microcrystalline cellulose, lactose, sucrose, pregelatinized starch, or dextrin, preferably one or more of microcrystalline cellulose, lactose, or dextrin. The binder is selected from one or more of methylcellulose, sodium carboxymethylcellulose, ethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, gelatin, povidone or polyethylene glycol, preferably one or more of sodium carboxymethylcellulose, gelatin or povidone. The disintegrant includes but is not limited to one or more of sodium carboxymethyl starch, croscarmellose sodium and crospovidone. The lubricant is selected from one or more of polyethylene glycol, sodium lauryl sulfate, talcum powder or magnesium stearate, and is preferably crospovidone or croscarmellose sodium. According to one embodiment of the invention, the auxiliary materials in the medicament comprise microcrystalline cellulose, sodium carboxymethylcellulose and crospovidone.
In certain embodiments, artemisia scoparia can be the only active ingredient in the medicament for treating pulmonary fibrosis. In other embodiments, the medicament for treating pulmonary fibrosis may also comprise other active ingredients having the effect of treating pulmonary fibrosis besides the artemisia scoparia, or comprise active ingredients which do not have the effect of treating pulmonary fibrosis per se but can assist the artemisia scoparia in playing the role of treating pulmonary fibrosis.
The medicament of the invention can form a medicinal preparation for improving the SOD content and the GSH content in serum. Furthermore, the medicament of the invention forms a pharmaceutical preparation for reducing the content of MDA in serum. SOD is superoxide dismutase. GSH is reduced glutathione. MDA is malondialdehyde.
SOD is an antioxidant metalloenzyme existing in organisms, can catalyze superoxide anion free radical disproportionation to generate oxygen and hydrogen peroxide, and plays a vital role in body oxidation and antioxidant balance.
GSH, chemical name N- (N-L-gamma-glutamyl-L-cysteinyl) glycine, molecular formula C10H17N3O6S, molecular weight 307.33.
MDA is used as a degradation product of lipid peroxide, and the content of MDA can reflect the degree of lipid peroxide in a body, and indirectly reflects the degree of damage of cells or the body.
In the pharmaceutical preparation with unit dose, the using amount of the artemisia scoparia extract is 0.95-3.95 g, preferably 1.15-3.90 g, still preferably 1.85-3.90 g, and more preferably 2.25-3.90 g. According to a specific embodiment of the invention, in the medicine for treating pulmonary fibrosis, the unit dosage of the medicine preparation contains 2.25-3.90 g of artemisia scoparia extract. When the dosage of artemisia scoparia is within the range, the artemisia scoparia is convenient to take and exert the efficacy, and the side effect is reduced.
The efficacy of the drug for treating pulmonary fibrosis in the present invention can reduce collagen fibers in the interstitium. After the artemisia scoparia is administrated, the phenomena of inflammatory cell infiltration, alveolar septal thickening, fibroblast proliferation and collagen deposition are improved. The artemisia scoparia can obviously improve the contents of SOD and GSH in serum and obviously reduce the content of MDA in the serum.
Preparation example-preparation of Artemisia scoparia extract
Grinding herba Artemisiae Scopariae, sieving with No. 2 sieve, soaking 100g of sieved herba Artemisiae Scopariae powder in water, and extracting under reflux for 3 times; the amount of water used in each time is 1000mL, the soaking is carried out for 5h each time, and the heating reflux extraction is carried out for 4h each time; mixing extractive solutions, filtering, and concentrating under reduced pressure to obtain 19.3g herba Artemisiae Scopariae extract. Refrigerating in a refrigerator at 4 deg.C, and diluting with water for dissolving.
Experimental example 1
1. Animal model making and experiment method
The animals are healthy SD rats with the weight of 300-350 g, and purchased from Yinss laboratory animal technology, Inc. in Changchun city.
Rats were randomly divided into 6 groups of blank control group, bleomycin model control group (model control group), artemisia scoparia dosing group (three doses of 100mg/kg, 200mg/kg and 400mg/kg, respectively, and artemisia scoparia extract prepared in the preparation example) and prednisone hydrochloride positive control group (5mg/kg), and 10 rats were added to each group. The test drugs are administered to each group by intragastric administration 1 time per day until sacrifice, and intragastric distilled water is administered to the model control group and the blank control group. Except the blank group, the other groups construct a rat pulmonary fibrosis model by injecting 5mg/kg of bleomycin into the trachea at one time; the blank control group is characterized in that physiological saline with the same volume is injected into the trachea at one time, rats in each group are sacrificed at 14 days after modeling, and lung tissues and blood are taken for subsequent experiments.
2. Observation indicator and method for measuring same
And (3) carrying out HE and Masson staining on the lung tissue, namely, fixing the right posterior lung lobe of the rat in neutral formalin solution, and carrying out HE staining and Masson staining on a conventional paraffin-embedded section to evaluate the damage of the lung tissue and the degree of pulmonary fibrosis.
2.1 Paraffin embedding and sectioning of tissues
2.1.1 taking out the posterior lobes of the right lung of each group respectively and fixing the posterior lobes in 4 percent paraformaldehyde for 24 hours;
2.1.2 absorbing paraformaldehyde, adding phosphate buffer solution for soaking, changing every 8 hours, continuously storing for 72 hours at 4 ℃;
2.1.3 opening the oven, setting the temperature at 62 ℃, and dissolving paraffin;
2.1.4 cutting each lung tissue into small pieces of 0.2-0.3 cm, then dehydrating with alcohol gradient (the concentration of alcohol is 30%, 50%, 70%, 80%, 90%, 95%, 100%), and replacing every 30 min;
2.1.5 putting into 50% alcohol and 50% xylene solution for 30min, taking out, and then putting into xylene to observe lung tissue mass until the lung tissue mass is transparent;
2.1.6 putting pre-melted 50% alcohol and 50% dimethylbenzene for 30min, and then respectively putting pre-melted paraffin twice, each time for 2 h;
2.1.7 putting the mixture into a pre-melted 100% paraffin paper box for solidification, and storing the mixture at 4 ℃;
2.1.8 cutting the tissue into 5-10 μ M thick continuous sections with a microtome, placing the sections flat on a flat plate with the smooth surface facing upwards;
2.1.9 placing the thin paraffin section on the water surface (water temperature 40 deg.C), stretching, and sticking on the pretreated glass;
baked at 2.1.1040 ℃ overnight for dyeing.
2.2HE staining procedure
2.2.1 baking: placing the slices formed in the step 2.1 in a thermostat at 80 ℃ for 1 h;
2.2.2 dewaxing: dewaxing xylene I for 10min and dewaxing xylene II for 20 min;
2.2.3 dehydration: dehydrating with 100% ethanol for 5min for 2 times, dehydrating with 95% ethanol for 5min for 2 times, standing in 85% ethanol for about 1min, standing in 75% ethanol for about 1min, and drying with absorbent paper;
2.2.4 rinsing: washing with distilled water for 2min twice;
2.2.5 staining: staining with hematoxylin for 5 min;
2.2.6 slightly rinsed with tap water;
2.2.7 differentiation: soaking in 1% hydrochloric acid alcohol solution for 5-10 s (observing that the section turns red from blue);
2.2.8 bluing: washing with tap water for about 25 min;
2.2.90.5% eosin for 2 min;
dehydrating with 2.2.1095% ethanol for 5min for 2 times, and drying with absorbent paper;
dehydrating with 2.2.11100% ethanol for 5min for 2 times, and drying with absorbent paper;
2.2.12 xylene, and drying with absorbent paper after being transparent for 5min twice;
2.2.13 neutral gum was mounted and observed under a mirror.
2.3Masson staining procedure
2.3.1 conventional dewaxing of the lung tissue sections formed in step 2.1 to water;
2.3.2Masson composite dye liquor for dyeing for 5-10 min;
2.3.3 soaking in 2% glacial acetic acid solution for a while;
2.3.4 putting the mixture into 1% phosphoric acid water solution for 3-5 min and then spin-drying;
2.3.5 dyeing with aniline blue aqueous solution for 5 min;
2.3.6 dehydration with alcohol gradient, xylene I, II transparency, and neutral gum sealing.
2.4 detection of MDA content in serum (Thiobabital acid method)
2.4.1 test principle: MDA (malondialdehyde) can combine with thiobarbituric acid (TBA) to form a red product. The product has a maximum absorption peak at 532 nm. Since the substrate of this reaction is TBA, this detection method is also called TBA method.
2.4.2 operating steps:
(1) setting a blank tube, a standard tube and a measuring tube, wherein 100 mu l of absolute ethyl alcohol is added into the blank tube, 100 mu l of standard substance (tetraethoxypropane 10nmol/ml) is added into the standard tube, and 100 mu l of sample to be measured is added into the measuring tube.
(2) Add 100. mu.l reagent one, vortex and mix for 1 min.
(3) Add 1.5ml of reagent two and reagent three separately and mix by vortexing.
(4) And (3) taking out the test tube, cooling the test tube by flowing water for 40min, centrifuging the test tube at room temperature of 3500rpm for 10min, sucking supernatant, adding the supernatant into a 96-well plate, wherein each well is 200 mu l, and each sample is provided with 3 multiple wells. OD values were measured at 532nm, and the average value was taken as the measured OD value. And (5) adjusting zero by double distilled water.
Note: because the sample has no hemolysis and lipemia, only 2 samples are made in each batch of the standard tube and the blank tube, and the blank tube is used for replacing the control tube. In the operation step, a kit is adopted for detection, and the kit is purchased from Nanjing to build a bioengineering institute, and has the model of A003-1-2.
2.5 detection of SOD content in serum (WST-1 method)
The method comprises the following operation steps:
(1) and setting a control blank, a control blank hole, a measurement hole and a measurement blank hole, adding 20 mu l of double distilled water into the control hole and the control blank hole, and adding 20 mu l of a sample to be measured into the measurement hole and the measurement blank hole.
(2) Mu.l of enzyme diluent was added to control and assay blank wells, and 20. mu.l of enzyme working solution was added to control and assay wells.
(3) Adding 200 μ l substrate application solution, mixing by vortex, incubating at 37 deg.C for 20min, and measuring OD at 450 nm.
Note: in the operation step, a kit is adopted for detection, and the kit is purchased from Nanjing to build a bioengineering institute, and has the model of A001-3-2.
2.6 detection of GSH content in serum (colorimetric method)
The method comprises the following operation steps:
(1) a blank well, a standard well and a measurement well are set, 100. mu.l of reagent I (stock solution) is added to the blank well, 100. mu.l of standard substance (20. mu.M GSH standard solution) is added to the standard well, and 100. mu.l of sample to be measured (supernatant) is added to the measurement well.
(2) Add 100. mu.l of reagent two and 25. mu.l of reagent three, respectively.
(3) Mixing, standing for 5min, and measuring absorbance of each well with an enzyme-labeling instrument at 405 nm.
Note: in the operation step, a kit is adopted for detection, and the kit is purchased from Nanjing to build a bioengineering institute, and has the model of A006-2-1.
3. Results of the experiment
3.1 evaluation of the improvement of Artemisia scoparia on rats with pulmonary fibrosis by using HE staining of lung tissue
Fig. 1 shows the effect of artemisia scoparia on HE staining of rats with pulmonary fibrosis. As shown in FIG. 1, the pulmonary alveoli of the rats in the blank control group were morphologically normal, had thin walls, and were not infiltrated with inflammatory cells in the pulmonary interstitium. In the model control group, thickening of alveolar spaces appears after administration of bleomycin, and inflammatory cell infiltration can be seen; the sheet-like solid change can be seen, and the solid change area has more inflammatory cell infiltration, fibroblast proliferation and collagen deposition. In the artemisia scoparia administration group (the artemisia scoparia low-dose group, the artemisia scoparia medium-dose group and the artemisia scoparia high-dose group), the phenomena of inflammatory cell infiltration, thickening of alveolar spaces, fibroblast proliferation and collagen deposition are improved after the artemisia scoparia administration. The artemisia scoparia low-dose group, the artemisia scoparia medium-dose group and the artemisia scoparia high-dose group are in concentration gradient to improve the damage of the lung; the effect of the artemisia scoparia high-dose group is the best and is equivalent to that of a positive control group.
3.2 evaluation of the Effect of Artemisia scoparia on the improvement of rats with pulmonary fibrosis by Masson staining of pulmonary tissue
FIG. 2 shows the effect of Artemisia scoparia on Masson staining of rats with pulmonary fibrosis at different concentrations.
As shown in FIG. 2, pulmonary alveolar structures of the lung tissues of rats in the blank control group were substantially normal. In the model control group, pulmonary fibrosis of different degrees appears in each group after the model is made by bleomycin, wherein, the phenomena of pulmonary alveolus collapse and fusion of the pulmonary tissues, pulmonary alveolar wall widening and interstitial collagen fiber increase of the model control group are obvious. The pulmonary alveoli structure of the artemisia scoparia administration group (the artemisia scoparia low-dose group, the artemisia scoparia medium-dose group and the artemisia scoparia high-dose group) is partially damaged, the alveolar wall is widened and thickened, and the phenomenon of collagen fiber increase is improved. Compared with the model control group, the artemisia scoparia dosing group has less increase of collagen fibers in the stroma. The artemisia scoparia low-dose group, the artemisia scoparia medium-dose group and the artemisia scoparia high-dose group are in concentration gradient to improve the damage of the lung; the effect of the artemisia scoparia high-dose group is the best and is equivalent to that of a positive control group.
3.3 detecting the contents of SOD, GSH and MDA in the serum of the rat
FIG. 3 shows the results of measuring the amount of GSH in rat serum in each group. FIG. 4 shows the results of measuring the SOD content in the serum of rats in each group. FIG. 5 shows the results of measuring the amount of MDA in rat serum in each group. Each group refers to blank control group, model control group, artemisia scoparia low-dose group, artemisia scoparia medium-dose group, artemisia scoparia high-dose group and positive control group.
In FIGS. 3, 4 and 5, # # represents a significant difference between the normal group and the model group, P < 0.01; # represents significant difference between the normal group and the model group, P < 0.05; the administered group was significantly different from the model group, P < 0.01.
When the body is damaged, the system generates a large amount of oxygen radicals. These oxygen radicals in turn attack polyunsaturated fatty acids in the biological membrane to cause lipid peroxidation, formation of lipid peroxides and new oxygen radicals, etc., resulting in damage to tissue cells. MDA is used as a degradation product of lipid peroxide, and the content of MDA can reflect the degree of lipid peroxide in a body, and indirectly reflects the degree of damage of cells or the body. Thus, antioxidants are also used in the treatment of pulmonary interstitial fibrosis.
SOD has the ability of resisting free radical damage, and the activity of SOD can indirectly reflect the capability of organism for removing oxygen free radical and the severity of tissue oxidation reaction. GSH (glutathione) is a free radical scavenging system present in the body, and the activity of glutathione peroxidase varies significantly in some pathological conditions.
As can be seen from fig. 3, 4 and 5, compared with the model control group, the artemisia scoparia high-dose group can significantly increase the contents of SOD and GSH in serum and significantly reduce the content of MDA in serum. The artemisia scoparia medium dosage group can obviously improve the SOD content in serum and obviously reduce the MDA content in the serum. The artemisia scoparia low-dose group and the artemisia scoparia medium-dose group can slightly improve the content of GSH in serum. Compared with the positive control group, the artemisia scoparia high-dose group has equal or better effect on improving the SOD content and the GSH content in serum and reducing the MDA content in serum. The above results indicate that artemisia scoparia can improve the degree of pulmonary fibrosis induced by bleomycin, and we preliminarily conclude that the mechanism of improving pulmonary fibrosis is probably related to antioxidation. In general, the effect of the artemisia scoparia high-dose group is optimal, and the result reaches or even exceeds that of the positive control group.
The present invention is not limited to the above-described embodiments, and any variations, modifications, and substitutions which may occur to those skilled in the art may be made without departing from the spirit of the invention.
Claims (10)
1. Application of artemisia scoparia in preparing medicine for treating pulmonary fibrosis is disclosed.
2. The use of claim 1, wherein the artemisia scoparia is artemisia scoparia medicinal powder or an artemisia scoparia extract.
3. The use of claim 2, wherein the artemisia scoparia is an artemisia scoparia extract.
4. The use according to claim 3, wherein the medicament forms a pharmaceutical formulation for the treatment of pulmonary fibrosis, the pharmaceutical formulation comprising artemisia scoparia and a pharmaceutically acceptable excipient.
5. The use of claim 4, wherein the artemisia scoparia is the only active ingredient in the medicament for treating pulmonary fibrosis.
6. The use according to claim 4, wherein the medicament forms a pharmaceutical formulation for increasing the content of superoxide dismutase and reduced glutathione in serum.
7. Use according to claim 4, characterized in that the medicament forms a pharmaceutical preparation for reducing the content of malondialdehyde in serum.
8. The use of any one of claims 4 to 7, wherein the artemisia scoparia extract is prepared by the following steps:
soaking the sieved artemisia scoparia medicinal material powder in water, heating and refluxing for extraction for 1-4 times, combining water extracting solutions, carrying out solid-liquid separation, and concentrating to obtain an artemisia scoparia extract; wherein the amount of water used in each time is 8-15 times of the weight of the artemisia scoparia medicinal material powder, and the soaking time is 2-6 hours; the time for each extraction is 2-6 h.
9. The use of claim 8, wherein the pharmaceutical formulation comprises 0.95-3.95 g of artemisia scoparia extract per unit dose.
10. The use of claim 9, wherein the pharmaceutical formulation comprises 1.15 to 3.90g of artemisia scoparia extract per unit dose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110916462.8A CN113456684B (en) | 2021-08-11 | 2021-08-11 | Application of artemisia scoparia in preparation of medicine for treating pulmonary fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110916462.8A CN113456684B (en) | 2021-08-11 | 2021-08-11 | Application of artemisia scoparia in preparation of medicine for treating pulmonary fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113456684A true CN113456684A (en) | 2021-10-01 |
| CN113456684B CN113456684B (en) | 2022-09-13 |
Family
ID=77866343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110916462.8A Active CN113456684B (en) | 2021-08-11 | 2021-08-11 | Application of artemisia scoparia in preparation of medicine for treating pulmonary fibrosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113456684B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101669979B (en) * | 2009-10-09 | 2012-07-11 | 新疆维吾尔自治区药物研究所 | Artemisia scoparia extractive and production method and applications thereof |
| CN105832793A (en) * | 2016-05-24 | 2016-08-10 | 新疆维吾尔自治区药物研究所 | Application of artemisia scoparia extract for preparing medicine for treating pneumonia caused by streptococcus pneumonia or/and beta hemolytic streptococcus |
-
2021
- 2021-08-11 CN CN202110916462.8A patent/CN113456684B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101669979B (en) * | 2009-10-09 | 2012-07-11 | 新疆维吾尔自治区药物研究所 | Artemisia scoparia extractive and production method and applications thereof |
| CN105832793A (en) * | 2016-05-24 | 2016-08-10 | 新疆维吾尔自治区药物研究所 | Application of artemisia scoparia extract for preparing medicine for treating pneumonia caused by streptococcus pneumonia or/and beta hemolytic streptococcus |
Non-Patent Citations (1)
| Title |
|---|
| 阿如汗等: "滨蒿的化学成分、药理作用及质量标准研究概况", 《中国民族医药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113456684B (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10086032B2 (en) | Method for preparing a Camellia nitidissima Chi lipid-lowering and hypoglycemic agent | |
| WO2021203614A1 (en) | Pharmaceutical composition for treatment of coronavirus diseases and preparation method therefor and application thereof | |
| US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
| RU2759382C2 (en) | Drug for injection based on saponin b4 pulsatilla | |
| US20090285913A1 (en) | Trachelospermi Caulis Extract Composition for the Treatment and Prevention of Inflammatory Diseases | |
| CN111787909A (en) | Composition containing berberine | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| WO2010081264A1 (en) | Pharmaceutical composition for preventing and treating diabetic nephropathy and preparation method thereof | |
| CN100574768C (en) | A kind of anticancer pharmaceutical composition and its production and use | |
| CN101856418B (en) | Pharmaceutical preparation for preventing nephritis and preparation method thereof | |
| JP2021512997A (en) | Separated windproof polysaccharides and their uses | |
| CN113456684A (en) | Application of artemisia scoparia in preparation of medicine for treating pulmonary fibrosis | |
| CN102153630B (en) | A kind of cyclic octapeptide and its preparation method and application in pharmacy | |
| CN100482266C (en) | Medical composite prepared by sarcandra and oldenlandia | |
| CN113559140B (en) | Application of edelweiss in preparation of medicine for treating pulmonary fibrosis | |
| CN115300586A (en) | A kind of traditional Chinese medicine composition for resisting urate renal deposition and preparation method thereof | |
| KR102279105B1 (en) | Composition for preventing or treating renal disease comprising Zizyphus jujuba MILL extract | |
| CN102641342A (en) | Traditional Chinese medicine extract for treating nephropathy and preparation method | |
| CN102204990B (en) | Medicine extract for reducing sugar content and preventing diabetic angiopathy and preparation method thereof | |
| CN113559141B (en) | Application of artemisia capillaris for preparing medicine for treating pulmonary fibrosis | |
| CN1111412C (en) | Notoginseng total saponin soft capsule and its preparation process | |
| CN114588212A (en) | New use of traditional Chinese medicine water lettuce for resisting heart failure | |
| CN1923229B (en) | Pharmaceutical composition comprising notoginseng extract, Danshen extract and puerarin | |
| CN110559286A (en) | Application of loganin aglycone in preparation of medicine for preventing or treating renal insufficiency | |
| WO2022228095A1 (en) | Application of prismatomeris connata y. z. ruan root extract in preparation of medicine for treating pulmonary fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |